CT Imaging Correlates of Genomic Expression for Oral Cavity Squamous Cell Carcinoma

REFERENCES

1. 1.↵
   1. Ferlay J,
   2. Shin HR,
   3. Bray F,
   4. et al

   . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Jemal A,
   2. Siegel R,
   3. Xu J,
   4. et al

   . Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Leemans CR,
   2. Braakhuis BJ,
   3. Brakenhoff RH

   . The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9–22

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Argiris A,
   2. Karamouzis MV,
   3. Raben D,
   4. et al

   . Head and neck cancer. Lancet 2008;371:1695–709

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Agrawal N,
   2. Frederick MJ,
   3. Pickering CR,
   4. et al

   . Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154–57

   Abstract/FREE Full Text
6. 6.↵
   1. Spector ME,
   2. Gallagher KK,
   3. Light E,
   4. et al

   . Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head Neck 2012;34:1727–33

   CrossRefPubMed
7. 7.↵
   1. Makkat S,
   2. Luypaert R,
   3. Stadnik T,
   4. et al

   . Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings–preliminary results. Radiology 2008;249:471–82

   CrossRefPubMed
8. 8.↵
   1. Diehn M,
   2. Nardini C,
   3. Wang DS,
   4. et al

   . Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 2008;105:5213–18

   Abstract/FREE Full Text
9. 9.↵
   1. Furnari FB,
   2. Fenton T,
   3. Bachoo RM,
   4. et al

   . Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683–710

   Abstract/FREE Full Text
10. 10.↵
    1. Leo C,
    2. Giaccia AJ,
    3. Denko NC

    . The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol 2004;14:207–14

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Maia AC Jr..,
    2. Malheiros SM,
    3. da Rocha AJ,
    4. et al

    . MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005;26:777–83

    Abstract/FREE Full Text
12. 12.↵
    1. Shimizu H,
    2. Kumabe T,
    3. Shirane R,
    4. et al

    . Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. AJNR Am J Neuroradiol 2000;21:659–65

    Abstract/FREE Full Text
13. 13.↵
    1. Emblem KE,
    2. Scheie D,
    3. Due-Tonnessen P,
    4. et al

    . Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. AJNR Am J Neuroradiol 2008;29:1664–70

    Abstract/FREE Full Text
14. 14.↵
    1. Jenkinson MD,
    2. du Plessis DG,
    3. Smith TS,
    4. et al

    . Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884–91

    Abstract/FREE Full Text
15. 15.↵
    1. Kanematsu M,
    2. Osada S,
    3. Amaoka N,
    4. et al

    . Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver: correlation with angiographically assisted CT. AJR Am J Roentgenol 2004;183:1585–93

    PubMed
16. 16.↵
    1. Emblem KE,
    2. Bjornerud A,
    3. Mouridsen K,
    4. et al

    . T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. J Cereb Blood Flow Metab 2011;31:2054–64

    CrossRefPubMed
17. 17.↵
    1. Zinn PO,
    2. Mahajan B,
    3. Sathyan P,
    4. et al

    . Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One 2011;6:e25451

    CrossRefPubMed
18. 18.↵
    1. Rubin Grandis J,
    2. Melhem MF,
    3. Gooding WE,
    4. et al

    . Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824–32

    FREE Full Text
19. 19.↵
    1. Pectasides E,
    2. Rampias T,
    3. Kountourakis P,
    4. et al

    . Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin Cancer Res 2011;17:2947–54

    Abstract/FREE Full Text
20. 20.↵
    1. Bauman JE,
    2. Michel LS,
    3. Chung CH

    . New promising molecular targets in head and neck squamous cell carcinoma. Curr Opin Oncol 2012;24:235–42

    CrossRefPubMed
21. 21.↵
    1. Choi BB,
    2. Kim SH,
    3. Kang BJ,
    4. et al

    . Diffusion-weighted imaging and FDG PET/CT: predicting the prognoses with apparent diffusion coefficient values and maximum standardized uptake values in patients with invasive ductal carcinoma. World J Surg Oncol 2012;10:126

    CrossRefPubMed
22. 22.↵
    1. Mahdey HM,
    2. Ramanathan A,
    3. Ismail SM,
    4. et al

    . Cyclin D1 amplification in tongue and cheek squamous cell carcinoma. Asian Pac J Cancer Prev 2011;12:2199–204

    PubMed
23. 23.↵
    1. Feng Z,
    2. Guo W,
    3. Zhang C,
    4. et al

    . CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS One 2011;6:e26399

    CrossRefPubMed
24. 24.↵
    1. van Diest PJ,
    2. Michalides RJ,
    3. Jannink L,
    4. et al

    . Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 1997;150:705–11

    PubMedWeb of Science
25. 25.↵
    1. Stransky N,
    2. Egloff AM,
    3. Tward AD,
    4. et al

    . The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157–60

    Abstract/FREE Full Text
26. 26.↵
    1. Chung CH,
    2. Zhang Q,
    3. Hammond EM,
    4. et al

    . Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2011;81:331–38

    CrossRefPubMed
27. 27.↵
    1. Smith BD,
    2. Smith GL,
    3. Carter D,
    4. et al

    . Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 2000;18:2046–52

    Abstract/FREE Full Text